| Adverse event | Placebo# | Tralokinumab | ||||
| Combined tralokinumab | 150 mg | 300 mg | 600 mg | |||
| Subjects | 47 | 146 | 47 | 51 | 48 | |
| At least one adverse event | 17 (36.2) | 70 (47.9) | 20 (42.6) | 25 (49.0) | 25 (52.1) | |
| Asthma¶ | 3 (6.4) | 16 (11.0) | 5 (10.6) | 5 (9.8) | 6 (12.5) | |
| Headache | 2 (4.3) | 13 (8.9) | 6 (12.8) | 1 (2.0) | 6 (12.5) | |
| Nasopharyngitis | 4 (8.5) | 10 (6.8) | 3 (6.4) | 3 (5.9) | 4 (8.3) | |
| Bacteriuria | 0 (0.0) | 8 (5.5) | 2 (4.3) | 2 (3.9) | 4 (8.3) | |
| Decreased neutrophil count | 3 (6.4) | 6 (4.1) | 3 (6.4) | 1 (2.0) | 2 (4.2) | |
| Influenza-like illness | 2 (4.3) | 6 (4.1) | 1 (2.1) | 2 (3.9) | 3 (6.3) | |
| Urinary tract infection | 0 (0.0) | 6 (4.1) | 3 (6.4) | 1 (2.0) | 2 (4.2) | |
| Crystalluria | 0 (0.0) | 5 (3.4) | 1 (2.1) | 1 (2.0) | 3 (6.3) | |
| Diarrhoea | 0 (0.0) | 5 (3.4) | 0 (0.0) | 0 (0.0) | 5 (10.4) | |
| Decreased lymphocyte count | 3 (6.4) | 4 (2.7) | 2 (4.3) | 1 (2.0) | 1 (2.1) | |
| Eosinophilia | 1 (2.1) | 4 (2.7) | 1 (2.1) | 0 (0.0) | 3 (6.3) | |
| Bronchitis | 3 (6.4) | 3 (2.1) | 2 (4.3) | 1 (2.0) | 0 (0.0) | |
Data are presented as n or n (%). The adverse events are ordered by frequency in combined tralokinumab group. #: one subject did not receive study medication; ¶: increase in asthma symptoms or asthma exacerbations.